Trial Profile
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Ipilimumab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 04 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 04 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 27 Jan 2023 Results performing Integrative transcriptome-based analysis in subjects treated on study , evaluating mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease, published in the Blood